Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 2/20 | 0.30 |
| ▸ | PPARA | Q07869 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1455116 | 0.85 | SLC6A4 (0.35) | PPARGPPARAALDH1A1 | |
| SCHEMBL12856847 | 0.83 | PTGES (0.40) | KMT2AMEN1ACHEDRD2DRD4 | |
| SCHEMBL1454451 | 0.81 | SLC7A5 (0.36) | PPARGPPARAALDH1A1 | |
| SCHEMBL1454205 | 0.80 | SIGMAR1 (0.35) | KMT2AMEN1ACHEDRD2DRD4 | |
| SCHEMBL9315284 | 0.80 | KMT2A (0.36) | KMT2AMEN1ACHEDRD2DRD4 | |
| SCHEMBL15871120 | 0.79 | ACHE (0.38) | KMT2AMEN1ACHEMAPTNPSR1 | |
| SCHEMBL12952589 | 0.78 | ACHE (0.44) | KMT2AMEN1ACHEMAPTNPSR1 | |
| SCHEMBL14420323 | 0.76 | KMT2A (0.36) | KMT2AMEN1ACHEMAPTNPSR1 | |
| SCHEMBL1455125 | 0.75 | SLC6A4 (0.37) | KMT2AMEN1MAPTPPARGPPARA | |
| SCHEMBL17108359 | 0.73 | PPARG (0.45) | KMT2AACHEMAPTNPSR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910617-B2 | Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound | SANKYO COMPANY, LIMITED (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20070191468-A1 | Amino alcohol compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1733724-A1 | AMINO ALCOHOL COMPOUND | Sankyo Company, Limited (JP) | 2006-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191468-A1 | Amino alcohol compound | ADH1A, ADH1C, BCAT1 | KMT2A 400/4885MEN1 3109/4885ACHE 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.